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Abstract
Background: CCR7 and MUC1 are correlated with lymph node metastasis in ESCC, but the role of MUC1 in the
CCR7-induced lymphatic metastasis and the underlying molecular mechanism is still unclear.
Methods: The expression of CCR7 and MUC1 was detected in the ESCC samples by IHC, and the clinical
significance of CCR7 and MUC1 in ESCC was analyzed. The expression of CCR7 and MUC1 in ESCC cell lines was
detected by qRT-PCR and western blot. The effect of CCL21 on the migration and invasion of ESCC cells was
determined by transwell assay. The activity of MUC1 promoter was determined by luciferase reporter assay. The
activation of Erk, Akt and Sp1 was detected by western blot and the binding of Sp1 to the MUC1 promoter was
determined by ChIP.
Results: The co-expression of CCR7 and MUC1 was detected in 153 ESCC samples by IHC, and both were
correlated with lymph node metastasis, regional lymphatic recurrence and poor prognosis. Correspondingly,
increasing levels of MUC1 mRNA and protein were detected in the ESCC cell lines KYSE410 and Eca9706 after
treatment with CCL21 in a time- and dose-dependent manner. Furthermore, silencing MUC1 could remarkably
suppress the invasion and migration of ESCC cells induced by CCL21. Moreover, heterologous CCR7 promoted the
invasion and migration of KYSE150 and up-regulated MUC1 expression. Increasing levels of activated ERK1/2 and
Akt were detected in KYSE410 after treating the cells with CCL21, and inhibiting the activation of ERK1/2 but not
Akt caused the increased transcription of MUC1. Finally, the phosphorylation of Sp1 induced by ERK1/2 and
subsequent increases in the binding of Sp1 to the muc1 promoter at −99/−90 were confirmed to cause the
up-regulation of MUC1 induced by CCL21-CCR7.
Conclusions: Our findings suggested that MUC1 plays an important role in CCL21-CCR7-induced lymphatic
metastasis and may serve as a therapeutic target in ESCC.
Background
Esophageal squamous cell carcinoma (ESCC) is one of
the most common digestive tumors worldwide [1].
Surgery still remains the first choice of treatment for
resectable ESCC, but the therapeutic effect is not
always favorable, and the 5-year survival rate of patients is
approximately 30–50 %; more than half of patients
develop recurrence within 2–3 years after undergoing
surgery [2, 3]. TNM staging is the main parameter used to
predict recurrence and prognosis, but it sometimes lacks
sensitivity and accuracy. Therefore, finding relevant
biological molecules may assist in identifying patients
at high risk for recurrence, and elucidating the underlying
molecular mechanism would present clinical advantages
in the treatment of this disease.
The process of cancer metastasis consists of a series of
sequential and interrelated steps, including detachment
from primary sites, intravasation, survival in the circula-
tion and translocation to target organs, extravasation
and colonization [4, 5]. However, very little is known
about the molecular mechanisms that regulate cancer
cells’ directional invasion into specific organs. According
to the homing theory, the metastasis of certain tumor
cells to specific organs results from chemotaxis: the
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chemokines highly expressed in target organs could
attract and capture tumor cells by binding with the che-
mokine receptors expressed on the surface of tumor
cells [6, 7]. As a member of chemokine receptor family,
C-C chemokine receptor type 7 (CCR7) is mainly lo-
cated on the membrane of mature dendritic and T cells,
and it could induce the “homing” of dendritic and T cells
to the lymph node by binding with its specific ligands
CCL19 and CCL21, which are highly expressed in the
endothelium of lymphatic vessels and secondary lymph
nodes [8, 9]. Interestingly, studies have identified the up-
regulation of CCR7 in various types of malignant tu-
mors, such as breast cancer, gastric cancer, and prostate
cancer, and have revealed its function in promoting
lymph node metastasis [10–12].
MUC1 is a transmembrane heterodimer protein with
two subunits: the MUC1 N-terminal subunit (MUC1-N)
contains variable numbers of tandem repeats that are ex-
tensively glycosylated. MUC1-N associates with the cell
surface by binding to the transmembrane MUC1 C-
terminal subunit (MUC1-C), which is mainly located on
the apical borders of normal epithelial cells [13]. The ab-
errant expression of MUC1 has been well documented
in various cancers and is correlated with advanced
tumor progression and metastasis potential; further-
more, several fundamental works revealed that MUC1-C
may function as an oncogene in the progression of
cancers by interacting with many biological molecules,
such as ICAM-1, β-catenin, EGFR, c-Src, and p65, to
promote cell motility, adhesion, proliferation, and sur-
vival [14–17]. Therefore, the overexpression of MUC1
may predict a more aggressive biological behavior in
several types of cancers.
Our previous studies revealed that the expression of
CCR7/MUC1 is correlated with regional lymphatic re-
currence in pN0 ESCC patients [18, 19]; however, there
are few reports of MUC1 expression in ESCC and no
available information on the cross-talk between MUC1
and CCR7 in the progression of lymphatic metastasis.
In this study, we hypothesized that the CCL21-CCR7
axis may facilitate the lymphatic metastasis of ESCC
via MUC1, further explored the role of MUC1 and




A total of 153 ESCC patients who underwent esophagec-
tomy in the Department of Thoracic Surgery at the pro-
vincial hospital affiliated with Shandong University from
January 2006–June 2009 were enrolled in this study. The
inclusion criteria were as follows: (1) Squamous cell car-
cinoma of the middle thoracic esophagus diagnosed by
postoperative pathology with staging from I–III; (2) no
preoperative chemotherapy or radiotherapy; (3) no con-
traindications to surgery, and all patients underwent
Ivor-Lewis esophagectomy with complete resection: no
residual tumor cells were present on upper or lower cut-
ting edge as verified by pathology, lateral margins with
no residual focus to the naked eye, and two-field lymph
node dissection; (4) a complete 5-year follow-up, and
the first location of recurrence was regional lymphatic
metastasis; and (5) no severe preoperative complications.
TNM staging was determined by the criteria established
by the International Union Against Cancer (UICC) in
2009 and lymph node dissection was undertaken accord-
ing to the lymph node mapping system for esophageal
cancer established by the American Joint Committee on
Cancer (AJCC) in 1997. Written informed consent was
obtained from all patients, and the study protocol was
approved by the Institutional Ethics Committee of the pro-
vincial hospital affiliated with Shandong University accord-
ing to Guide for Chinese Ethics Review Committees.
Cell lines and culture
The human ESCC cell lines Eca9706, KYSE150,
KYSE410 and KYSE450 were from the Cancer Institute
and Hospital, Chinese Academy of Medical Sciences,
China. The cells were cultured in Roswell Park Memor-
ial Institute (RPMI) 1640 enriched with 1 % penicillin/
streptomycin (sigma, USA) and 10 % fetal bovine serum
(HyClone, USA). Cell culture plates were maintained in
humidified incubators at 37 °C in a 5 % CO2 incubator.
Real-time RT-PCR
Total cell RNA was extracted using the RNAiso Plus
(TaKaRa, Japan) according to the manufacturer’s instruc-
tions. The purity of RNA was measured and determined
by UV spectrophotometry; the OD260/280 value was
1.8–2.0. Quantitative real-time RT-PCR was performed
using a LightCycler 480 II Real-Time PCR System
(Roche, Frankfurt, Germany). The cycling conditions
were as follows: 5 min at 95 °C for preincubation and 45
amplification cycles of 10 s at 95 °C, 10 s at 60 °C and
10 s at 72 °C with the SYBR® Premix Ex Taq™ (TaKaRa,
Japan) according to the manufacturer’s instructions. PCR
primers were as follows: MUC1, 5′-TCA GCT TCT
ACT CTG GTG CAC AA-3′ (forward) and 5′-ATT
GAG AAT GGA GTG CTC TTG CT-3′ (reverse);
GAPDH, 5′-AGA AGG CTG GGG CTC ATT TG-3′
(forward) and 5′-AGG GGC CAT CCA CAG TCT TC-3′
(reverse). PCR was repeated at least twice in all samples.
The expression level of MUC1 mRNA was calculated
using a ratio of MUC1 mRNA against GAPDH mRNA.
Immunohistochemistry
The immunohistochemistry studies of MUC1 and CCR7
were performed by the streptavidin peroxidase method.
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The formalin-fixed, paraffin-embedded tissues were cut
into 4-μm sections. The sections were deparaffinized
and incubated with 3 % hydrogen peroxide. Specific
mouse polyclonal anti-MUC1 antibody (Abcam, UK)
and specific rabbit polyclonal anti-CCR7 antibody
(Abcam, UK) were used at a dilution of 1:100 and incu-
bated at 4 °C overnight. The subsequent steps were
followed according to the instructions of the secondary
biotinylated antibody kit (Zhongshan Biotech, China).
As negative controls, the primary antibody was replaced
by the phosphate buffered saline. All sections were ex-
amined by two independent pathologists who were
blinded to the clinical data. The immunohistochemical
score (IHS) was calculated by combining the proportion
score (percentage of positively stained cells) with the
staining intensity score. The proportion score ranged from
0 to 4, as follows: 0 (<5 %), 1 (5–24 %), 2 (25–49 %), 3
(50–74 %), and 4 (≥75 %). The staining intensity was
scored as follows: 0 (negative), 1 (weak), 2 (moderate), and
3 (strong). The proportion score and staining intensities
score were then multiplied to generate the IHS for each
case. Cases with IHS ≥8 were considered to be positive for
the expression of CCR7 or MUC1.
Stable transfection by lentivirus
The lentiviral vector containing specific siRNA targeting
MUC1 (si-MUC1, specific sequence targeting MUC1:
5′-ACC AAT TTC TCG GAC ACT T-3′)/Sp1 (si-Sp1,
specific sequence targeting Sp1: 5′-TTT CGC GAA
GTA CTC CTC ACT-3′), full-length cDNA of CCR7
(−CCR7) or a nonsense sequence serving as a scrambled
negative control (si-NC/-NC) were obtained from
Genechem (Shanghai, China). The ESCC cell lines were
transfected by the lentivirus according to the manufac-
turer’s instructions with an MOI of 50:1. Twenty-four
hours later, the medium containing lentivirus was replaced
with complete medium containing puromycin (1 μg/ml)
to remove the stable transfected cells.
Immunoblotting
The total protein of cultured cells was extracted and
measured as described previously. To detect the phos-
phorylated protein, the phosphatase inhibitor was used
with a working concentration of 1 mM in the total pro-
tein extraction. The proteins were transferred to
Hybond-P polyvinylidene difluoride membranes in
trans-buffer containing 25 mM Tris and 185 mM glycine
(pH 8.3) together with 20 % methanol. After transfer, the
membranes were blocked for 1 h in blocking buffer
(TBS containing 0.1 % Tween-20, TBST, supplemented
with 5 % non-fat dry milk) and the membranes were in-
cubated overnight at 4 °C with antibodies (MUC1,-
MUC1-C and p-Sp1 were obtained from Abcam, UK; p-
ERK, ERK, p-akt and akt were obtained from CST, USA;
GAPDH and β-actin were obtained from Santa Cruz,
USA) in blocking buffer. After being washed three times
with TBST, the membranes were incubated with second-
ary antibody conjugated with horseradish peroxidase
(HRP) anti-mouse/rabbit IgG (Santa Cruz, USA) for 1 h
at room temperature. The bands were visualized by an
enhanced chemiluminescence (ECL) detection system
(LAS-4000 MINI System, GE, California, USA).
Cell immunofluorescence
The starved KYSE410 or Eca9706 cells were treated with
PBS or CCL21 (Peprotech, USA) for 24 h, and the cells
were fixed by 4 % paraformaldehyde for 20 min and in-
cubated with Triton X-100 (0.3 %). After being blocked
by goat serum for 30 min, the cells were incubated with
the primary antibodies anti-MUC1-C or anti-Sp1 over-
night. Then, the cells were washed with PBS three times
and incubated with PE-conjugated secondary antibody
(Santa Cruz, USA) for 1 h. After being washed with PBS
three times and incubated with DAPI for 15 mint, cover-
slips were sealed with a drop of Prolong Gold antifade
reagent (Invitrogen, USA). Images were acquired by laser
scanning microscopy (Eclipse Ti, Nikon, Tokyo, Japan)
and analyzed by NIS-Elements D 3.2.
Cell migration and invasion assay
Cell migration and invasion experiments were assayed in
triplicate using a 24-well transwell setup and polycar-
bonate nucleopore filters with an 8-μm pore size (Merck
Millipore Bioscience, Germany). Prior to each experi-
ment, cells were deprived of FBS for 24 h. For invasion
assays, the inserts were pre-coated with Matrigel (BD
Biosciences, Belgium) diluted 1:10 in serum-free Ham’s
F10, and the Matrigel was allowed to solidify for 1 h at
37 °C. For migration assays, the inserts were left uncoated.
Each upper well was loaded with starved 2 × 105cells in a
total volume of 200 μL of serum-free medium. The lower
wells of the chamber were loaded with 600 μL of 1640
medium. Invasion assays were allowed to proceed for
36 h, whereas migration assays were incubated for 12 h.
For migration assays, CCL21 (200 ng/mL) or PBS was
added to the lower chamber, while for invasion assay,
CCL21 (200 ng/mL) or PBS was added to the upper
chamber. Any cells remaining on top of the insert were re-
moved by scraping. Migrated cells attached to the under-
side were fixed for 10 min in methanol and stained with
ethanol-based crystal violet solution. Cells were observed
under a microscope (Eclipse Ti, Nikon, Tokyo, Japan) and
all cells in five random visual fields in the middle of the
membrane were counted.
Transient transfection and luciferase assay
KYSE410 cells were seeded in RPMI 1640 with 10 % FBS
in 24-well plates and incubated for 24 h at 37 °C, 5 %
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CO2, to 70–80 % confluence. Medium was replaced with
serum-free RPMI 1640, and the cells were starved for
another 24 h. The medium was replaced by RPMI 1640,
1 % FBS, and the cells were transfected using X-
tremeGENE HP DNA Transfection Reagent (Roche,
Germany) according to the manufacturer’s instructions.
The MUC1 promoter-firefly luciferase reporter plasmid
(MUC1-pGL2b), MUC1 promoter −97/−96(GG→AA)
mutant-firefly luciferase reporter plasmid (MUC1
mutant-pGL2b), the empty pGL2b vector and phRL-TK
internal control plasmid encoding Renilla luciferase and
were constructed as described previously [16]. Briefly,
sample DNA was mixed with 2.0 μL of X-tremeGENE
and diluted with OPTI-MEMI (Invitrogen, USA) to a
final volume of 100 μl. After15 min of incubation at
room temperature, 600 μL of the transfection mixture
was added to each well. After 6 h, the medium contain-
ing transfection mixture was replaced with RPMI 1640
with 1 % FBS. Then, the cells were treated with 200 ng/
ml CCL21 or PBS as control for 12 h at 37 °C. To inhibit
the activation of ERK1/2/Akt, the transfected KYSE410
cells were pretreated with U0126/MK2206 (Cell Signaling,
USA) for 30 min before CCL21 treatment. Luciferase
activity was determined using the Dual Luciferase
assay system (Promega) according to the manufacturer’s
instructions for the SpectraMax M2 (Molecular Devices,
California, USA). Luciferase activity driven by the MUC1
promoter was normalized to the internal control by
calculating the ratio of firefly luciferase activity to
Renilla luciferase activity in each sample and was
expressed as the percentage of MUC1 promoter activity
relative to control samples.
Chromatin immunoprecipation assay
ChIP assay was performed using the Pierce™ Agarose
ChIP Kit according to the manufacturer’s instructions
(Thermo Fisher, USA). Briefly, 2 × 106 KYSE410 cells
pretreated with PBS or CCL21 were treated with 1 %
formaldehyde at room temperature for 10 min to cross-
link DNA with its binding proteins. Then, the glycine
solution was added and incubated at room temperature
for 5 min to stop the cross-linkage reaction. After being
washed with ice-cold PBS three times, the nuclei of the
cross-linked cells were extracted and then sheared with
0.3 μL MNase (10U/μL) in a 37 °C water bath for
15 min. After centrifugation, the nuclei were resus-
pended in 50 μL nuclear extraction buffer and incubated
in ice for 15 min. Then, 45 μL digested chromatin was
added to 450 μL IP dilution buffer and incubated with
Sp1 antibody (Abcam, UK) or rabbit IgG as a negative
control at 4 °C overnight with the remaining 5 μL of
digested chromatin as input. After incubation, the
immunoprecipitated sample was mixed with 20 μL Protein
A/G plus agarose resin and incubated for 1 h at 4 °C. After
being washed three times, 150 μL IP elution buffer was
added to the resin and incubated at 65 °C for 30 min, then
mixed with 6 μL of 5 M NaCl and 2 μL of 20 mg/mL pro-
teinase K to reverse the protein-DNA cross linkage; while
the input sample was mixed with 150 μL of IP elution buf-
fer, 6 μL of 5 M NaCl and 2 μL of 20 mg/mL proteinase K
and incubated at room temperature. The eluted IP and in-
put samples were placed at 65 °C for 1.5 h, and then the
DNA was extracted and precipitated with ethanol for the
PCR test. The MUC1 primer was as follows: 5′-TCT TAT
TTC TCG GCC GCT CTG CTT-3′ (forward), 5′-TGG
GTA GGG TAC AAG GGC TCT AAT-3′ (reverse).
The automatic electrophoresis gelatin image formation
analysis system (Alphalmager™ 2000, Alpha Innotech,
California, USA) was used to determine the gray value of
the amplified bands.
Statistical analysis
SPSS 19.0 was used to create databases for data analysis.
For continuous variables, Student’s t-test was performed.
The correlation between CCR7/MUC1 protein expression
and pathological parameters was determined by the chi-
square test or Fisher’s exact probability test (two-tailed
tests). Survival and recurrence rates were calculated by the
Kaplan-Meier method and analyzed by the log-rank test.
Results
Co-expression of CCR7 and MUC1 in ESCC tissue
To determine the correlation of CCR7 and MUC1 in
ESCC tissue, we detected the expression of CCR7 and
MUC1 by IHC in 153 ESCC samples. The immunostain-
ing showed that CCR7 was mainly detected on the
membrane and in the cytoplasm of tumor cells. MUC1
was mainly located in the nuclei and cytoplasm while
partially on the membrane. The positive expression of
CCR7 was detected in 88 samples with the remaining 65
samples staining negative, and the positive expression of
MUC1 was detected in 97 samples with the remaining
56 samples staining negative. The IHS of MUC1 in
group with positive CCR7 expression was 8.011 ± 2.673
(mean ± SD), while the IHS of MUC1 in group with
negative CCR7 expression was 5.773 ± 3.454 (mean ± SD).
The MUC1 expression was higher in ESCC samples
with positive CCR7 expression than in the negative
samples (P < 0.001, Fig. 1a, b).
The expression of CCR7 and MUC1 correlated with the
lymph node metastasis, regional lymphatic recurrence
and poor prognosis
In 89 patients with lymph node metastasis, there were
60 (67.4 %) patients with positive CCR7 expression, and
67 (75.3 %) patients with positive MUC1 expression. In
64 patients without lymph node metastasis, there were
29 (45.3 %) patients with positive CCR7 expression and
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22 (34.4 %) patients with positive MUC1 expression.
The expressions of CCR7 and MUC1 were both posi-
tively correlated with lymph node metastasis (Table 1).
Meanwhile, in the 89 patients with lymph node metasta-
sis, 53 patients co-expressed CCR7 and MUC1 (59.6 %),
seven patients only expressed CCR7 (13.2 %), 18 patients
only expressed MUC1 (20.2 %), and 11 patients did not
express CCR8 or MUC1 (12.4 %). The co-expression of
CCR7 and MUC1 was also positively correlated with
lymph node metastasis (Table 2).
Fig. 1 Co-expression of CCR7 and MUC1 in ESCC sample. a The expression of CCR7 and MUC1 in ESCC detected by IHC; b the immunoreactivity
score of MUC1 in group with CCR7 positive expression and CCR7 negative expression group; c the 3-year regional recurrence curve of patients
with CCR7 and MUC1 positive/negative expression; d the 5-year survival curve of patients with CCR7 and MUC1 positive/negative expression
Shi et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:149 Page 5 of 15
The 3-year recurrence rates of patients with positive
and negative CCR7 expression were 59.1 and 32.3 %, re-
spectively (P < 0.01). The 3-year recurrence rates of pa-
tients with positive and negative MUC1expression were
59.8 and 26.8 % (P < 0.001), respectively. The 3-year re-
currence rate of patients with positive CCR7 and MUC1
expression, positive CCR7 and negative MUC1 expres-
sion, negative CCR7 and positive MUC1 expression, and
negative CCR7 and MUC1 expression were 73.2, 47.1,
57.7 and 38.5 %, respectively (P = 0.004, Fig. 1c).
The 5-year survival rates of patients with positive and
negative CCR7 expression were 28.4 and 52.3 %, respect-
ively (P < 0.01). The 5-year survival rates of patients with
positive and negative MUC1 expression were 29.9 and
53.6 % (P < 0.01), respectively. The 5-year survival rates
of patients with positive CCR7 and MUC1 expression,
positive CCR7 and negative MUC1 expression, negative
CCR7 and positive MUC1 expression, and negative
CCR7 and MUC1 expression were 26.8, 35.3, 38.5 and
61.5 %, respectively (P < 0.001, Fig. 1d).
CCL21-CCR7 up regulated MUC1 expression in ESCC cell
lines
First, we detected the expression of MUC1 and CCR7 in
KYSE150, KYSE410, KYSE450 and Eca9706 cells: higher
mRNA and protein expression levels of CCR7 and MUC1
were found in KYSE410 and Eca9706, while the lowest ex-
pression levels of CCR7 and MUC1 were detected in
KYSE150 (Fig. 2a, b). We then wondered whether activat-
ing CCR7 by its specific ligands could regulate the expres-
sion of MUC1. The ESCC cell lines were treated with
CCL21 (100 ng/mL), and qRT-PCR showed a remarkable
increases in the mRNA level in KYSE410, KYSE450 and
Eca9706 cells with a higher expression level of CCR7,
Table 1 Clinical characteristics and its relationship with CCR7/
MUC1 expression
Clinical characteristic CCR7 positive
expression









Length of tumor(cm) 0.98 0.08
<3 cm 20/35 20/35
3 ~ 5 cm 42/72 50/72
>5 cm 26/46 27/46
Invasion depth 0.27 0.07
T1 11/25 11/25
T2 44/76 49/76
T3 + T4a 33/52 37/52





























Male 57/116 12/116 17/116 30/116
Female 14/37 5/37 9/37 9/37
Age(year) 0.61
≥50 52/108 11/108 20/108 25/108




<3 cm 16/35 4/35 4/35 11/35
3 ~ 5 cm 34/72 8/72 16/72 14/72
>5 cm 21/46 5/46 6/46 14/46
Invasion depth 0.170
T1 9/25 2/25 2/25 12/25
T2 35/76 9/76 14/76 18/76




Yes 53/89 7/89 18/89 11/89
No 18/64 10/64 8/64 28/64
Differentiation 0.06
Well/moderate 26/67 8/67 9/67 24/67
Low 45/86 9/86 17/86 15/86
Weight loss 0.2
Yes 12/23 3/23 6/23 2/23




Yes 46/78 8/78 15/78 9/78
No 25/75 9/75 11/75 30/75
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Fig. 2 CCL21 induced the up-regulation of MUC1 in ESCC cell lines. a, b the mRNA and protein expression level of MUC1 and CCR7 in ESCC cell
lines; c: CCL21 induced the increasing MUC1 mRNA in ESCC cells. KYSE150, KYSE410, KYSE450 and Eca9706 were starved for 24 h and then treated
with CCL21 at a concentration of 100 ng/ml for 12 h, then cells were harvested for the qRT-PCR; d, e CCL21 up regulated mRNA of MUC1 in a
time and dose dependent way. Eca9706 and KYSE410 were starved for 24 h and then treated with CCL21 at a concentration of 0, 25, 50, 100,
200 ng/ml for 12 h or cells were treated with CCL21 at a concentration of 100 ng/ml for 0, 2, 6, 12 or 24 h. Then cells were harvested for qRT-
PCR; f, g increasing of MUC1-C in KYSE410 and Eca9706 after treated with CCL21 at concentration of 0, 25,50, 100, 200 ng/ml for 24 h confirmed
by immunoblotting; h, f blocking CCR7suppressed the up-regulation of MUC1 induced by CCL21. Eca9706 and KYSE410 were pretreated by CCR7
antibody (1 ug/mL) or IgG as control, then treated by 100 ng/ml for 24 h, then cells were harvested for detection of MUC1 by immunoblotting;
j expression of MUC1 in KYSE410 and Eca9706 treated with PBS or CCL21(100 ng/mL) detected by immunofluorescence. Each data point
represents the mean ± SD of three repeated experiments. *P < 0.05
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while there was no significant change of MUC1 in
KYSE150 with a lower expression level of CCR7 (Fig. 2c).
These results above were consistent to the co-expression
of MUC1 and CCR7 in ESCC tissue samples. Further-
more, we found that CCL21 could increase the mRNA
level of MUC1 in a dose- and time-dependent manner in
KYSE410 and Eca9706 cells, and the saturated dose was
approximately 50–100 ng/ml. The increase of MUC1
mRNA was detectable approximately 2 h after being
treated with CCL21, and the highest level was detected
at approximately 12–24 h (Fig. 2d, e). The western
blot also confirmed that CCL21 could increase the
expression of MUC1-C protein in a dose-dependent
manner (Fig. 2f, g). To further confirm the role of
CCR7 in the up-regulation of MUC1 induced by
CCL21, we used the specific antibody to block CCR7,
and the results showed that blocking CCR7 could sig-
nificantly suppress the up-regulation of MUC1-C in-
duced by CCL21 (Fig. 2h, i).
CCL21-CCR7 promoted the migration and invasion of
ESCC cell lines in vitro
Because the migration and invasion abilities of tumor cells
are crucial for metastasis, we performed a transwell assay
to evaluate the effect of the CCL21-CCR7 axis on the
migration and invasion of KYSE410 and Eca9706. The re-
sults showed that CCL21 could significantly enhance the
migration and invasion of KYSE410 and Eca9706. Further-
more, blocking CCR7 with the specific antibody (R&D,
USA) significantly suppressed the migration and invasion
of KYSE410 and Eca9706 induced by CCL21 (Fig. 3).
Silencing MUC1 inhibited the migration and invasion of
ESCC cell lines induced by CCL21
We have proven that the CCL21-CCR7 axis can pro-
mote the migration and invasion of ESCC cells in vitro
and also increase the level of the MUC1-C protein. Con-
sidering MUC1-C as an oncogene in cancers, we as-
sumed that the increasing expression of MUC1-C may
be responsible for the migration and invasion induced
by CCL21. Therefore, we established siMUC1-KYSE410
and Eca9706 for transwell assays and the results showed
that silencing MUC1 could remarkably suppress the mi-
gration and invasion induced by CCL21 (Fig. 3).
CCL21-CCR7 increased the up-regulation of MUC1 via
activating ERK1/2
We detected the increasing phosphorylation of Akt1 and
ERK1/2 in KYSE410 and Eca9706 after treatment with
CCL21, while blocking CCR7 could remarkably suppress
the activation of ERK1/2 and Akt induced by CCL21
(Fig. 4a, b). To identify whether Akt1 and ERK1/2 path-
way were responsible for the up-regulation of MUC1,
KYSE410 and Eca9706 cells were pretreated with the
specific inhibitor of Akt(MK2206) or ERK1/2(U1026),
and the results showed that U1026 remarkably sup-
pressed the up-regulation of MUC1 induced by CCL21,
while MK2206 did not significantly suppress the up-
regulation of MUC1 (Fig. 4c). Moreover, the luciferase
reporter assay showed that inhibiting the activation of
ERK1/2 but not Akt could suppress the activity of the
MUC1 promoter after treatment with CCL21 (Fig. 4d).
These results confirmed that the activation of ERK1/2
was responsible for the up-regulation of MUC1 induced
by the CCL21-CCR7 axis.
Activation of SP1 induced by p-ERK1/2 was responsible
for the increasing transcription of MUC1 gene
Though our results showed that p-ERK1/2 was respon-
sible for the up-regulation of MUC1 transcription, the
underlying molecular mechanism still remained unclear.
Several studies revealed that the regulation of MUC1 ex-
pression occurs mainly on the transcriptional level and
that the SP1 binding site at −99/−90 on the promoter is
crucial for the transcription of MUC1 gene [20, 21], and
several fundamental works have proven that the phos-
phorylation of SP1 by Erk/Akt/PKC could regulate its
DNA binding ability [22]. Based on this, we explored the
role of Sp1 in the up-regulation of MUC1 induced by
CCL21-CCR7. The results showed that silencing Sp1
could abolish the increase of MUC1 induced by CCL21
(Fig. 5a, b); consistently, the mutant of the Sp1 binding
site on the MUC1 promoter at −97/−96(GG→AA) sig-
nificantly suppressed the MUC1 promoter activity in-
duced by CCL21 (Fig. 5c). These results confirmed the
important role of Sp1 in the CCL21-CCR7-induced up-
regulation of MUC1. Then, an increasing phosphoryl-
ation level of Sp1 at T453 (p-Sp1) was detected and the
accumulation of p-Sp1 in nuclei after treatment with
CCL21 was observed in KYSE410 (Fig. 5d, e), and inhi-
biting p-ERK1/2 could significantly suppress the phos-
phorylation of Sp1 and the accumulation of p-Sp1 in
nuclei (Fig. 5f, g). Subsequently, the ChIP assay con-
firmed an increased level of SP1 binding to the MUC1
promoter in the CCL21-treated group compared to the
control group, while inhibiting the activation of ERK1/2
could remarkably suppress the binding of SP1 to the
MUC1 promoter at −99/−90 in KYSE410 (Fig. 5h). All
of this evidence indicated that the ERK1/2-Sp1 pathway
is involved in the up-regulation of MUC1 induced by
CCL21-CCR7.
Heterologous expression of CCR7 promoted the
migration and invasion induced by CCL21 and also
up-regulation of MUC1
In this study, KYSE150 had the lowest CCR7 and MUC1
expression levels among ESCC cell lines. To further ex-
plore the role of CCL21-CCR7 in promoting migration
Shi et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:149 Page 8 of 15
Fig. 3 Silencing of MUC1 suppressed migration and invasion induced by CCL21. Cells were starved for 24 h and then seeding into the upper
chamber, for the migration assay CCL21 was added into the lower chamber at a concentration of 200 ng/ml and incubated for 12 h; for the
invasion assay the CCL21 was added into the upper chamber at a concentration of 200 ng/ml and incubated for 36 h. Cells on the lower surface
of the membrane were counted in five randomly selected fields. a CCL21 promoted migration and invasion of KYSE410 and Eca9706 while
blocking CCR7 could reverse migration and invasion induced by CCL21, and silencing MUC1 by siRNA targeted to MUC1 significantly suppressed
the migration and invasion induced by CCL21; b Total cell numbers on the lower surface of the membrane counted in five randomly selected
fields. Each data point represents the mean ± SD of 3 repeated experiments. *P < 0.05; Each datapoint represents the mean ± SD of three
repeated experiments. *P < 0.05
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and invasion and its role in inducing the expression of
MUC1, we established KYSE150-CCR7 and KYSE150-
NC by transfecting lentivirus containing cDNA of the
CCR7 gene or a nonsense sequence as a control. The
transwell assay showed that CCL21 remarkably pro-
moted the migration and invasion of KYSE150-CCR7
compared to the KYSE150-NC groups. Furthermore, a
remarkable increase in the expression of MUC1 was also
observed in the KYSE150-CCR7 compared to the
KYSE150 NC groups after treatment with CCL21 by
qRT-PCR and immunoblotting (Fig. 6).
Discussion
As a highly aggressive malignant tumor, the major risk
factor influencing the prognosis of ESCC patients is lymph
node metastasis, and the most common reason for the
failure of surgical treatment of ESCC is metastatic recur-
rence in regional lymph nodes. The metastasis of tumor
cells is a complex process involving multiple key steps,
and directional migration to the targeted organs is essen-
tial to achieve metastasis. The lymphatic metastasis of
tumor cells is quite similar to the “homing” of mature
lymphocytes to the secondary lymph node: with the guide
of chemokine receptors, the lymphocytes or tumor cells
could directionally migrate into targeted organs [5, 23]. As
a chemokine receptor, CCR7 has been proven to be in-
volved in lymphatic metastasis in various cancers, includ-
ing ESCC [24, 25], and the role of the CCL21-CCR7 axis
in inducing the directional migration and invasion of
tumor cells has also been proven [26–29]. Consistent with
these former studies, our results also showed that CCR7
was correlated with lymphatic metastasis, lymphatic re-
currence status and poor prognosis in ESCC. And we also
confirmed that CCL21 could promote the migration and
invasion of the ESCC cell lines KYSE410 and Eca9706 in
vitro. These findings confirmed the function of the
Fig. 4 Activation of ERK1/2 was responsible for the up-regulation of MUC1 induced by CCL21-CCR7. a The activation of ERK1/2 and Akt pathway
induced by CCL21, KYSE410 and Eca9706 cells were seeding into 6 well culture plate and starved overnight, then culture medium was replaced
by serum free medium contained CCL21 (100 ng/ml) and incubated for 0, 15, 30, 45, 60 min. Then cells were harvested for immunoblotting;
b Blocking CCR7 could suppress the activation of Akt and ERK1/2 pathway induced by CCL21 in KYSE410 and Eca9706; c, d Inhibiting activation
of ERK1/2 but not Akt could suppress the up-regulation of MUC1-C protein. The starved KYSE410 and Eca9706 cells were pretreated by DMSO as
controll, U0126 or MK2206 for 30 min, then cells were treated with PBS or CCL21 (100 ng/ml). For detecting p-ERK1/2, p-Akt and MUC1-C, cells
were harvested after incubated with CCL21 for 15 min, 30 min and 24 h respectively; e Inhibiting ERK1/2 but not Akt could remarkably suppress
the activity of MUC1 promoter, KYSE410 and Eca9706 cells transfected with MUC1-pGL2b plasmid were pretreated with DMSO as control, U0126
or MK2206 and then treated with PBS or CCL21 (100 ng/ml) for 12 h, then cells were harvested to detect the relative luciferase activity. Each
datapoint represents the mean ± SD of three repeated experiments. *P < 0.05
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Fig. 5 (See legend on next page.)
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CCL21-CCR7 axis in promoting lymph metastasis in
ESCC.
The aberrant overexpression of MUC1 has been de-
tected in ESCC and is correlated with lymphatic metas-
tasis and poor prognosis [17, 30]; Qing Y et al. further
confirmed that MUC1-C could promote lymph node
metastasis in ESCC by up-regulating the expression of
MMP13 [31]. Here we also confirmed that overexpres-
sion of MUC1 correlated with lymph node metastasis
and recurrence in ESCC patients. Though MUC1 is a
heterodimer protein localized on the cellular membrane,
many fundamental works have confirmed the constant
accumulation of MUC1-C in the cytoplasm, nuclei and
mitochondria of cancer cells due to the MUC1-autoclea-
vage [15] and further revealed its role in promoting me-
tastasis by inducing epithelial mesenchymal transition
(EMT), promoting cell motility, and up-regulating MMPs
and uPA [32–35]. We also detected the localization of
MUC1 in the nuclei and cytoplasm in the ESCC tissue
samples and the cell lines, and this indicates the possible
accumulation of MUC1-C in ESCC. However, the bio-
logical significance of the subcellular localization of
MUC1 in ESCC still needs to be explored.
Though the CCL21-CCR7 axis may promote the ag-
gressive biological behavior of ESCC cells, the key down-
stream molecules that regulate migration and invasion
are still unclear. Here, we revealed the potential role of
MUC1 in CCL21-CCR7-induced lymphatic metastasis in
ESCC. By analyzing the expression of CCR7 and MUC1
in 153 ESCC tissue samples, we found the co-expression
of CCR7 and MUC1 in ESCC, and the two molecules
were both correlated with lymph node metastasis and
prognosis; furthermore, the patients who co-expressed
CCR7 and MUC1 had the highest recurrence rate and
the lowest survival rate compared with the rest of the
groups. Therefore, we speculated that there might be
CCR7-MUC1 crosstalk in the progression of metastasis.
Then, we identified the up-regulation of MUC1 mRNA
and the MUC1-C protein in Eca9706 and KYSE410 after
treatment with CCL21, and subsequent transwell assay
confirmed that silencing MUC1 remarkably inhibited the
migration and invasion of ESCC cell lines induced by
CCL21 in vitro. Moreover, KYSE150 cells with the heterol-
ogous expression of CCR7 exhibited not only more aggres-
sive biological behavior but also increasing MUC1 after
being treated with CCL21. All of these results indicated
that CCR7 could promote metastasis via the up-regulation
of MUC1 in ESCC, and the molecular mechanism of
MUC1 in promoting migration and invasion induced by
CCL21- CCR7 in ESCC still requires further investigation.
Research has revealed that the Akt and ERK pathways
are involved in the CCR7-induced migration of tumor
cells [36–39], and we also detected increased activation
of ERK1/2 and p-Akt in KYSE410 and Eca9706 cells
after treatment with CCL21. To identify whether acti-
vated ERK1/2 and Akt were responsible for the up-
regulation of MUC1 induced by CCL21, the ESCC cell
lines was pretreated with the corresponding specific in-
hibitor. The results showed that inhibiting the activation
of ERK1/2 could significantly suppress the transcription
of the MUC1 gene, and Koga T et al. also reported the
up-regulation of MUC1 induced by the TNFR-mediated
activation of ERK1/2 in lung cancer cells [40]. Though
Liao G et al. reported that the EGFR-mediated activation
of the PI3k-Akt pathway could promote the transcrip-
tion of the MUC1 gene [41], in this study, inhibiting the
activation of Akt1 by MK2206 did not remarkably affect
the expression of MUC1 in vitro.
Although our work proved that activated ERK1/2 was
responsible for the increased transcription of MUC1 in-
duced by CCL21-CCR7, the downstream signaling path-
way is still unclear. Previous studies have revealed that
the binding of SP1 to the MUC1 promoter at −99/−90 is
crucial for the transcriptional regulation of MUC1 gene,
and the phosphorylation of SP1 by ERK1/2 could alter its
binding affinity to the promoter of certain genes, such as
VEGF and erbB2, for transcriptional regulation [42, 43].
Therefore, we assumed that the ERK1/2-Sp1 pathway is
(See figure on previous page.)
Fig. 5 Phosphorylation of SP1 was responsible for the up-regulation of MUC1 induced by CCL21-CCR7. a, b Silencing Sp1 could remarkably
suppressed the up-regulation of MUC1 in KYSE410 and Eca9706 induced by CCL21. The starved siSp1-Eca9706, siNC-Eca9706, siSp1-KYSE410 and
siNC-KYSE410 were treated with CCL21(100 ng/mL) for 24 h, then cells were harvested for immunoblotting for MUC1-C; c Silencing Sp1/Mutant
of Sp1 binding site at −99/−97 could remarkably suppressed MUC1 promoter activity induced by CCL21. siSp1-Eca9706, siNC-Eca9706, siSp1-KYSE410
and siNC-KYSE410 transfected by MUC1-pGL2b luciferase reporter plasmid/KYSE410 and Eca9706 cells transfected by MUC1-pGL2b or MUC1 mutant-
pGL2b -firefly luciferase reporter plasmid were treated with PBS or CCL21(100 ng/mL) for 24 h, then cells were harvested for detecting the luciferase
activity; d Increasing phosphorylation of Sp1 induced by CCL21. Starved KYSE410 and Eca9706 cells were treated with CCL21(100 ng/mL) for 0, 0.5, 1,2
and 6 h, then cells were harvested for the immunoblot of p-Sp1; e The expression of p-Sp1 in KYSE410 treated with PBS or CCL21(100 ng/ml) for 6 h
detected by immunofluorescence; f Blocking CCR7 could suppress the phosphorylation of Sp1 induced by CCL21. The starved KYSE410 and Eca9706
cells pretreated with the CCR7 antibody or IgG as control, were treated with PBS or CCL21 for 6 h, then cells were harvested for the immunoblot of
p-Sp1; g Inhibiting ERK1/2 suppressed phosphorylation of SP1 induced by CCL21. Starved KYSE410 and Eca9706 cells were pretreated with DMSO as
control or U0126 for 30 min. After treated with PBS or CCL21(100 ng/mL) for 6 h, the cells were harvested for immunoblot; h Inhibiting ERK1/2
suppressed Sp1 binding to MUC1 promoter at −99/−97. Starved KYSE410 cells were pretreated with DMSO as control or U0126 for 0.5.
After treated with PBS or CCL21(100 ng/mL) for 12 h, the cells were harvested for the ChIP assay. The targeted DNA was amplified using
MUC1 primers with 40 cycles of PCR. Each datapoint represents the mean ± SD of three repeated experiments. *P < 0.05
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involved in the up-regulation of MUC1 gene transcription
induced by CCL21-CCR7. Correspondingly, we found in-
creased phosphorylation of SP1 at T453 and subsequent
increases in Sp1 binding to the MUC1 promoter at
−99/−90 after treatment with CCL21 in KYSE410.
And inhibiting the activation of ERK1/2 remarkably sup-
pressed the phosphorylation of SP1 at T453 and the bind-
ing of SP1 to the MUC1 promoter. All of these evidences
indicated the involvement of the ERK1/2- SP1 pathway in
the CCL21-induced expression of MUC1.
Conclusion
In conclusion, our study confirmed the role of MUC1 in
lymph node metastasis induced by CCL21-CCR7 in
ESCC and elucidated the possible phosphorylation of the
ERK1/2 and Sp1 pathways in the regulation of MUC1 by
Fig. 6 Heterologous CCR7 promoted migration and invasion and up-regulated expression of MUC1 in KYSE150. a Heterologous expression of
CCR7 up regulated the expression of MUC1 mRNA in KYSE150, KYSE150-CCR7 and KYSE150NC cells were starved and then treated with PBS or
CCL21(0, 25, 50, 100, 200 ng/mL) for 12 h and then harvested for qRT-PCR and the result showed the remarkable up-regulation of MUC1 in
KYSE150-CCR7 after treated with CCL21 compared to the KYSE150NC groups; b Heterologous expression of CCR7 up regulated the expression of
MUC1-C protein in KYSE150, KYSE150-CCR7 and KYSE150NC cells were starved and then treated with PBS or CCL21(100 ng/mL) for 24 h and then
harvested for immunoblot and the result showed the remarkable up-regulation of MUC1 in KYSE150-CCR7 after treated with CCL21 compared to
the KYSE150NC groups; c Heterologous expression of CCR7 promoted migration and invasion induced by CCL21, the starved KYSE150-CCR7 and
KYSE150NC cells were seeding into the upper chamber, for the migration assay CCL21 was added into the lower chamber at a concentration of
200 ng/ml and incubated for 12 h; for the invasion assay the CCL21 was added into the upper chamber and incubated for 36 h; d Total cell
numbers on the lower surface of the membrane counted in five randomly selected fields. Each data point represents the mean ± SD of
three repeated experiments. *P < 0.05
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CCL21-CCR7. Our results may help elucidate the mo-
lecular mechanism of lymph node metastasis in ESCC
and offer a theoretical basis for targeted therapy.
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